Equity Profile

TVTX

TRAVERE THERAPEUTICS

Health CareBiotechnology$4.3B

Feb23Thu

Post-Earnings Recap

ReportedQ4-2022After Close4:01 PM EST

Travere Therapeutics Beats on EPS, Stock Up 4.84%

Metric	Actual	Expected	Surprise
EPS	-$0.76	N/A	+26.71%
Revenue	N/A	N/A	N/A

management commentary, guidance changes, and full analysis available with Pro.

Travere Therapeutics Beats on EPS, Stock Up 4.84%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	-$0.76	N/A	+26.71%
Revenue	N/A	N/A	N/A

Management Commentary

Tone: Cautiously Optimistic

Overall, management expressed cautious optimism about their ongoing projects and the potential for future growth. They are focused on improving operational efficiency.

Management highlighted progress in their clinical programs.

They emphasized their commitment to advancing treatment options for patients.

There was a focus on operational efficiency moving forward.

What It Means

Travere Therapeutics reported a narrower-than-expected loss per share, which led to a positive stock reaction, increasing by 4.84%. The company's focus on advancing its clinical programs and improving efficiency suggests a commitment to long-term growth. However, the lack of revenue data and forward guidance leaves some uncertainty for investors.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Feb20

WMBReported

The Williams Companies, Inc.

RecapView

Feb20

NDSNReported

Travere Therapeutics Beats on EPS, Stock Up 4.84%

Metric	Actual	Expected	Surprise
EPS	-$0.76	N/A	+26.71%
Revenue	N/A	N/A	N/A

management commentary, guidance changes, and full analysis available with Pro.

Travere Therapeutics Beats on EPS, Stock Up 4.84%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	-$0.76	N/A	+26.71%
Revenue	N/A	N/A	N/A

Management Commentary

Tone: Cautiously Optimistic

Overall, management expressed cautious optimism about their ongoing projects and the potential for future growth. They are focused on improving operational efficiency.

Management highlighted progress in their clinical programs.

They emphasized their commitment to advancing treatment options for patients.

There was a focus on operational efficiency moving forward.

What It Means

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime